Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin 287 (Icodec) vs Insulin Degludec in Type 2 Diabetes
NCT02964104Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Insulin 287 + placebo with Insulin degludec + placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Nov 2016; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02964104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964104.